Hemophagocytic Lymphohistiocystosis Study Group
ID Number 07-0094Principal Investigator(s)
Gustavo Del Toro
Department(s) or Division(s)
The purpose of this study is to examine if the study drugs dexmethasone, VP-16, and cyclosporine A given at different times during the course of the disease improve the survival rates and reduce permanent disabilities of Hemophagocytic Lymphohistiocytosis (HLH). In addition, the investigators would like to gather more information on the nature, cause and course of HLH. The study drugs have not been approved by the Food and Drug Administration (FDA) specifically for the treatment of HLH. A child may qualify for participation in this study if he/she has been diagnosed with Hemophagocytic Lymphohistiocytosis.
Recruiting Patients: Yes